Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca's Baxfendy wins FDA approval for uncontrolled hypertension, targeting aldosterone synthesis following Ph3 success
Small molecule, cardiovascular, aldosterone synthase inhibitor, hypertension, combination therapy - Read more

GSK's Arexvy (respiratory syncytial virus vaccine) gains Japan label expansion for at-risk adults aged 18–49 following Ph3b data
Vaccine, infectious disease, recombinant protein vaccine, RSV, immunocompromised patients, respiratory disease - Read more

Boehringer Ingelheim's JASCAYD (nerandomilast) approved in Japan for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis following Ph3 success
Small molecule, pulmonary fibrosis, PDE4B inhibitor, idiopathic pulmonary fibrosis, antifibrotic - Read more

Boston Scientific invests $1.5B for 34% stake in MiRus, with option to acquire TAVR system for $3B
Equity investment, cardiovascular, medical devices, milestone payments, acquisition option - Read more

Fujifilm Healthcare Americas, Ardent Health partner on AI-enabled enterprise imaging platform across 30+ hospitals
Licensing deal, AI/ML, diagnostics, digital health, commercialization - Read more

Regeneron, Parabilis Medicines collaborate to create antibody-helicon conjugate drug class, $75M upfront, $2.3B deal
Research collaboration, peptide therapy, antibody-drug conjugate, oncology, milestone payments, equity investment - Read more

CellBxHealth, AdventHealth collaborate on CTC-based cancer monitoring across two multi-centre studies
Research collaboration, oncology, diagnostics, liquid biopsy, R&D - Read more

Kariya Pharmaceuticals, NeuraLight partner to advance brain-penetrant GLP-1 therapies using precision biomarker platform
Research collaboration, neurological, small molecule, diagnostics, R&D - Read more

AstraZeneca, Roche Diagnostics partner on three-year AI cancer biomarker adoption across nine Asian markets
Research collaboration, oncology, AI/ML, diagnostics, biomarkers - Read more

Edison Innovations, Illuminare Biotechnologies cement royalty-bearing licensing agreement supporting Illuminare-1 Phase II clinical trial
Licensing deal, small molecule, surgical/intraoperative imaging, royalties, clinical trials - Read more

Context Therapeutics, BioAtla amend CT-202 license, removing milestones for $4.5M upfront and $2M final payment
Licensing deal, oncology, bispecific antibody, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Vincentage's VCT220 (orforglipron rival) meets Ph3 primary endpoints for obesity, prompting China NMPA submission
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes - Read more

Ipsen's (corabotase) Ph2 data supports Ph3 advancement for long-acting neurotoxin targeting glabellar lines
Protein therapy, aesthetic medicine, neurotoxin, recombinant neuroinhibitor, glabellar lines - Read more

Merck & Co.'s (sacituzumab tirumotecan) hits Ph3 mark in endometrial cancer, beating chemotherapy in survival outcomes
Antibody-drug conjugate, cancer, small molecule, endometrial cancer, TROP2, non-small cell lung cancer - Read more

Microbiotica's MB097 shows positive Ph1b results combined with pembrolizumab in advanced melanoma with anti-PD-1 resistance
Microbiome therapy, cancer, combination therapy, melanoma, anti-PD-1 resistance, immune checkpoint inhibitor - Read more

NanoViricides closes ~$2M registered direct offering, broad-spectrum antiviral development
Infectious disease, antiviral, nanomedicine, clinical-stage - Read more

Accro Bioscience raises $50M Series C to advance immune mediated disease clinical pipeline
Autoimmune, small molecule, clinical-stage, ulcerative colitis - Read more

Full-Life Technologies raises $150M Series D, advancing radiotherapeutics pipeline and Belgium manufacturing
Radiopharmaceuticals, oncology, clinical-stage, manufacturing, prostate cancer - Read more

Wonderlab Bio receives undisclosed investment from Jetstream Venture Fund for R&D expansion
Cell therapy, regenerative medicine, iPSC, off-the-shelf, preclinical - Read more

Bristol Myers Squibb weighs $1B Houston manufacturing plant that could employ 500 people
Small molecule, manufacturing, strategic, major transaction - Read more

Revolution Medicines' (daraxonrasib) Ph3 RAS inhibitor on track for FDA approval in metastatic pancreatic ductal adenocarcinoma by Q3
Small molecule, cancer, RAS inhibitor, pancreatic cancer, non-small cell lung cancer - Read more

Quince Therapeutics merges with Orphai Therapeutics in reverse merger after rare disease phase 3 failure
Cell therapy, rare disease, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

BioMarin Pharmaceutical's BMN 401 (INZ-701) misses key Ph3 skeletal healing endpoint in ENPP1 deficiency
Protein therapy, rare disease, enzyme replacement therapy, ENPP1 deficiency, hypophosphatemic rickets - Read more

Novartis terminates plant contract with Chinese CDMO Porton Pharma Solutions, threatens $64M in legal claims
Small molecule, infectious disease, operational, financial - Read more

Supreme Court rejects IRA drug pricing challenges from AstraZeneca, Novo Nordisk, J&J, and others
Small molecule, multi-disease, regulatory, revenue impact, competitive - Read more

Amgen's Tavneos linked to 20 deaths in Japan, prompting Kissei to discourage new patient prescriptions
Small molecule, autoimmune, regulatory, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here